Clinical Study Tracks Medical Cannabis Outcomes in Patients Aged 65+

The study, supported by funding from the European Union, analyzed clinical data from 124 older adults receiving care at a specialized medical practice in Colombia. Researchers tracked symptom trajectories over time, recording baseline measurements alongside three-month follow-up assessments for 44 patients within the cohort.

How Low-Dose Regimens Handled Symptoms and Dosage 

Participants in the study presented primarily with musculoskeletal disorders, pain-related conditions, neurodegenerative diseases, and non-degenerative neurological disorders. The majority of individuals reported no prior experience with cannabis before beginning treatment.

Treating physicians evaluated symptoms using a standard four-point severity scale ranging from absent to severe. Researchers defined positive symptom evolution as a reduction of at least one point on the scale. 

“The first documented improvement occurred at visit 2 in 67.7% of patients with pain, 65.4% of those with insomnia, and 73.9% of those with mood or behavioral symptoms, with median times to first improvement of three, two, and one month, respectively,” the researchers wrote. 

Here is what key outcomes from the data say:

• Symptom Reduction Threshold: Approximately 91% of participants with follow-up data achieved at least a one-point reduction in the severity of their primary symptom.
• Time to Initial Improvement: Among patients reporting positive responses, median times to initial recorded improvement were one month for mood or behavioral symptoms, two months for sleep disturbances, and three months for chronic pain.
• Dosage Profiles: Effective clinical routines relied primarily on oral, oil-based formulations administered in low daily doses containing just a few milligrams of active cannabinoids, including THC, CBD, and CBG.
• Concomitant Medication: While total overall pharmaceutical usage across the cohort remained stable, 25% of participants were able to reduce or discontinue specific prescription medications under clinical supervision.

Study Limitations and the Path Ahead for Seniors’ Care

The authors noted that complete symptom resolution was rare, with most patients moving from moderate symptom intensity to mild levels over the course of follow-up. No patients in the cohort experienced a worsening of their primary symptoms during the assessment period.

Researchers emphasized several inherent methodological limitations. Because the research relied on an observational design without a control group, direct causal relationships between cannabinoid administration and symptom reduction cannot be definitively established. Additionally, the initial cohort size remains relatively small.

Nevertheless, these findings add to a growing body of scientific evidence suggesting that supervised medical cannabis may offer a viable therapeutic option for managing a variety of age-related health conditions. To build on their findings, the research team plans to launch larger studies across Colombia, Argentina, and Chile to better understand safety, treatment habits, and patient outcomes across different healthcare systems. 

Read more from Soft Secrets:

• Can Cannabis Help with Alzheimer’s?

• Study Finds No Link Between Cannabis and Dementia

• Are Costs for Medical Cannabis Reimbursed?

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional or physician before starting any new treatment, changing an existing regimen, or combining medical cannabis with prescription medications.